A Phase 2 Study of ARQ 197 in Patients With Microphthalmia Transcription Factor Associated Tumors.

Trial Profile

A Phase 2 Study of ARQ 197 in Patients With Microphthalmia Transcription Factor Associated Tumors.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2012

At a glance

  • Drugs Tivantinib (Primary)
  • Indications Renal cell carcinoma; Soft tissue sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ArQule
  • Most Recent Events

    • 24 Jul 2012 Actual end date changed from 17 Dec 2010 to Feb 2011 as reported by ClinicalTrials.gov.
    • 01 Jun 2012 Actual end date 17 Dec 2010 added as reported by EudraCT.
    • 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top